Nkarta NKTX 深 滬
已收盤 04-02 16:00:00 美东时间
2.32
+0.130
+5.94%
華盛通- 最 高2.325
- 今 開2.13
- 成交量 44.98万股
- 最 低 2.13
- 昨 收 2.19
- 總市值 1.65亿
- 52周最高 2.81
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 1.598
- 委 比 -23.78%
- 總股本 7129.05万
- 歷史最高 79.16
- 量 比 0.72
- 振 幅 8.90%
- 歷史最低 1.28
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Needham Maintains Buy on Nkarta, Raises Price Target to $11
Needham analyst Gil Blum maintains Nkarta (NASDAQ:NKTX) with a Buy and raises the price target from $10 to $11.
03-26 20:21
Nkarta Launches $100 Million At-the-Market Stock Offering
The latest update is out from Nkarta ( ($NKTX) ). On March 25, 2026, Nkarta, In...
03-26 18:41
Nkarta enters at-the-market equity distribution agreement; offering size grows to $100 million
Nkarta enters at-the-market equity distribution agreement; offering size grows to $100 million Nkarta entered into an at-the-market equity distribution agreement with Stifel, Nicolaus & Company for sales of common stock with aggregate gross proceeds of up to USD 100.0 million. Sales may be made from
03-26 18:01
Nkarta files $350M shelf offering, plans $100M ATM stock sale via Stifel
Nkarta (NKTX) filed a $350M mixed-securities shelf offering with the SEC to raise funds and plans to sell up to $100M in common stock (par value $0.0001) via an ATM deal with Stifel, Nicolaus & Compan...
03-26 15:41
Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 9.79 percent. This is a 5.71 percent decrease over losses of $(0.35) per share from the same
03-26 04:02
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Nkarta reported its financial results for Q4 and 2025, highlighting a cash balance of $295.1 million, which is expected to fund operations into 2029. The company advanced NKX019's dose escalation to 4 billion cells per dose, aiming to maximize B-cell depletion. Initial clinical data from Ntrust-1 and Ntrust-2 trials are planned for presentation in 2026.
03-25 20:01
Nkarta to Participate in Evercore Healthcare Conference
Nkarta, Inc., a clinical-stage biopharmaceutical company developing NK cell therapies for autoimmune diseases, announced its participation in the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025. A fireside chat will take place at 10:50 a.m. ET, with a live webcast available on Nkarta’s investor website and an archived replay for 90 days. The company specializes in allogeneic, off-the-shelf NK cell therapies designed for bro...
2025-12-02 12:09
